Literature DB >> 19255265

Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.

S Kiertiburanakul1, K Malathum, S Watcharananan, B Sathapatayavongs, S Sungkanuparph.   

Abstract

Skin rash associated with nevirapine (NVP) is common and efavirenz (EFV) is often used as a substitute. We aimed to determine the predicting factors for unsuccessful switching from NVP to EFV. A retrospective cohort study was conducted in HIV-infected patients who developed rash after taking NVP. There were 109 patients with a mean standard deviation (SD) age of 36.6 (7.4) years and 45% were males. Median (interquartile range) CD4 cell count and HIV RNA at the time of NVP initiation were 163 (50-273) cells/mm(3) and 4.6 (1.7-5.4) log copies/mL, respectively. Twenty (18.3%) patients subsequently developed EFV-associated rash. By logistic regression, history of drug allergy apart from NVP (odds ratio [OR] 11.42) and CD4 cell count <100 cells/mm(3) (OR 6.14) were significant predicting factors for EFV-associated rash. Two predicting factors for unsuccessful switching from NVP to EFV were found. Patients who have these factors need to have a close follow-up if EFV is substituted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255265     DOI: 10.1258/ijsa.2008.008231

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

1.  Severe eye complications from toxic epidermal necrolysis following initiation of Nevirapine based HAART regimen in a child with HIV infection: a case from Cameroon.

Authors:  Xavier Tchetnya; Calypse Asangbe Ngwasiri; Tiayah Munge; Leopold Ndemnge Aminde
Journal:  BMC Pediatr       Date:  2018-03-13       Impact factor: 2.125

2.  A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation.

Authors:  Sasisopin Kiertiburanakul; Somnuek Sungkanuparph; Kumthorn Malathum; Siriorn Watcharananan; Boonmee Sathapatayavongs; Angkana Charoenyingwattana; Surakameth Mahasirimongkol; Wasun Chantratita
Journal:  Open AIDS J       Date:  2009-07-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.